An interventional study of Standard PN and Patient Choice in Substance Use Disorders, sponsored by Yale University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Yale University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Substance-Related Disorders by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · Yale University.
Among the 63 studies in Substance-Related Disorders by Yale University, this one is the 12th largest by planned enrollment of the 59 interventional ones that give a count, is the only one that started in 2025, is one of 32 with no phase, and was the 61st registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 63 studies in Substance-Related Disorders by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18–50
Yale University · Sites in United States
Ages 18–50
Yale University · Sites in United States
Ages 18+ · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 11–15 · Healthy volunteers
By country, each count listing its studies:
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 5 · Phase 4 4
First in 1993; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 74 across the 59 interventional studies, 200 across the 4 observational. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in Substance-Related Disorders by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03539575Yale UniversityCB1R in Synthetic Psychoactive Cannabinoids | 2026-12 |
| NCT07768007Yale UniversityReal-time Opioid Study | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 63 studies in Substance-Related Disorders by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to compare the effectiveness of two Patient Navigation models of care to evaluate the proportion who initiate PrEP/ART and substance use/substance use disorder (SU/SUD) treatment. A standardized Patient Navigation (PN) arm will be compared with a shared decision-making model in the form of Patient Choice (PC) through the offer of a menu of existing community-based health service delivery options. This design will offer providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of Patient Navigation and Patient Choice models of care as potentially useful re-entry and relapse prevention treatment options.
This study will be done in two phases. Aim 1, the R61 portion of the project will be a Pilot Study, and Aim 2, the R33 portion of the project will be a Randomized Controlled Trail informed by the pilot.
The focus of this registration is Aim 2, the randomized controlled trial. The Aim 1 (R61) portion is registered with NCT06439329. In Aim 2 (R33), investigators will evaluate standard PN compared to PN+PC on participant outcomes, implementation outcomes and costs associated with implementing the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PNs are "near-peer" professionals who have shared lived experiences with participants and help them overcome barriers to accessing and engaging in quality care. PNs are trained and linked to PrEP/ART and SUD services. This manualized PN approach provides a complete assessment of participant needs, goal setting, and help with appointment scheduling.
Behavioral: Standard PN
PNs working in the PN + PC arm will be trained to engage participants in selecting from a menu of service options in their community. This menu of SUD and HIV prevention and treatment service delivery options will be created through bolstering and working with our Community Advisory Boards (CAB). PNs will also be trained to discuss sexual and substance use history with participants in order to provide education and motivation towards starting PrEP/ART and SUD treatment.
Behavioral: Standard PN · Behavioral: Patient Choice
Standard of care
Participants can select from a menu of options including brick and mortar services, Mobile Health Unit (MHU) or telehealth services.
Percentage of participants who initiate or re-initiate PrEP
Percentage of participants not living with HIV who initiate or re-initiate PrEP within the 6-month intervention period by self report
Time frame: 6 months
Percentage of participants who initiate or re-initiate ART
Percentage of participants living with HIV who initiate or re-initiate ART within the 6-month intervention period by self report
Time frame: 6 months
Percentage of participants that adhere to PrEP
Percentage of participants that adhere to PrEP
Time frame: 6 and 12 months
Percentage of participants retaining on PrEP
Percentage of participants retaining on PrEP
Time frame: 6 and 12 months
HIV incidence
HIV incidence \[binary\] for those testing negative using rapid point of care (POC) test over time
Time frame: 6 and 12 months
Percentage of participants that adhere to ART
Percentage of participants that adhere to ART
Time frame: 6 and 12 months
ART retention
For persons living with HIV (PLH), ART retention \[binary\]
Time frame: 6 and 12 months
Substance use treatment
Percentage of participants engaged in substance use disorder (SUD) treatment
Time frame: 6 and 12 months
HIV viral suppression
For PLH, HIV viral suppression, for those with HIV at time of randomization: the percent who maintain or achieve HIV viral load \< 200 copies/mL at 6 months
Time frame: 6 months
Retention in HIV PrEP/ART
Retention in HIV PrEP/ART care \[binary\]: defined as attending 2 or more visits in 6-months
Time frame: 6 months
Number of Participants Who Had Any Needle Sharing Activity to Assess HIV Risk Behavior
Number of Participants Who Had Any Needle Sharing Activity
Time frame: 6 and 12 months
Number of Participants Who Had Sex Without a Condom to assess HIV Risk Behavior
Number of Participants Who Had Vaginal or Anal Sex Without a Condom
Time frame: 6 and 12 months
Days of using opioids
Measured by Timeline Followback, which assesses self-reported alcohol and other drug use including opioid use
Time frame: 6 and 12 months
Number of participants with with overdose events
Number of participants with non-fatal and fatal overdose events
Time frame: 6 and 12 months
Percentage of participants with retention in SUD treatment
Retention in SUD treatment including but not exclusive to Medication for Opioid Use Disorder (MOUD) for Opioid Use Disorder (OUD)
Time frame: 6 and 12 months
Quality of Life assessed using PROMIS-PROPr
PROMIS-PROPr assesses general societal health. Total summary score ranges from -0.022, worse than dead, to 1, perfect health.
Time frame: 6 and 12 months
Change in Depression assessed using Patient Health Questionnaire-9 (PHQ-9)
Depression will be assessed using the PHQ-9. PHQ-9 is a 9-item validated questionnaire used to screen for depression with a range of scores from 0-45. A cumulative score of ≥10 is considered positive with lower scores indicating no or mild anxiety.
Time frame: 6 and 12 months
Recidivism: Reasons
Number of participants per reason for arrest/ incarceration/return-to-custody
Time frame: 6 and 12 months
Recidivism: Mean days in custody/incarcerated
Mean days in custody/incarcerated
Time frame: 6 and 12 months
Recidivism: Mean days to return
Mean days to return to custody/incarcerated
Time frame: 6 and 12 months
HIV and SU Stigma assessed using Substance Use Stigma Mechanisms Scale (SU-SMS)
Mean score for Enacted (6 items), Anticipated (6 items), and Internalized (6 items) scales. Each scale is scored 1-5, with higher scores indicating greater endorsement of substance use stigma
Time frame: 6 and 12 months
Percentage of participants diagnosed with SUD
Percentage of participants diagnosed with SUD using DSM-5
Time frame: Baseline and 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 25 months is below that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.